Home・Aktien・Viatris Inc

Viatris Inc

Geschlossen

BrancheGesundheitswesen

16.42 0.86

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

16.41

Max

16.61

Schlüsselkennzahlen
By Trading Economics
Einkommen	517M 176M
Verkäufe	-187M 3.5B
EPS	0.59
Dividendenrendite	2.73
Gewinnspanne	5.016
Angestellte	30,000
EBITDA	101M 644M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+10.59% upside

Dividenden
By Acuity
Dividendenrendite Branchendurchschnitt	2.73% 2.29%
Nächstes Ergebnis	5. Nov. 2026
Nächste Dividendenausschüttung	16. Sept. 2026
Nächstes Ex-Dividendendatum	21. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	2.8B 21B
Vorheriger Eröffnungskurs	15.56
Vorheriger Schlusskurs	16.42

Nachrichtenstimmung

By Acuity

50%

151 / 340 Ranking in Healthcare

Viatris Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Viatris Inc Prognose

Kursziel

By TipRanks

10.59% Vorteil

12-Monats-Prognose

Durchschnitt 18.17 USD 10.59%

Hoch 23 USD

Tief 12 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Viatris Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Viatris Inc – Dist abgegeben haben.

Stimmung

By Acuity

151 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.